Refine by
Deep Vein Thrombosis Dvt Articles & Analysis
14 news found
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). APEX-AV is a ...
Xarelto is approved for more venous and arterial thromboembolic (VAT) conditions than any other NOAC: The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors The treatment of pulmonary embolism (PE) in adults The treatment of deep vein thrombosis ...
ByBayer AG
It seems like a simple device – a little basket shaped wire that can be put into a vein to remove a blood clot. But it is in fact a pioneering piece of equipment that could save thousands of lives. It’s been used for the first time – on Jackie Field, from Eltham south east London, and cured her of deep vein ...
Rivaroxaban Rivaroxaban, as an antithrombotic drug, is widely used in the treatment and prevention of deep vein thrombosis (DVT) symptoms prior to hip or knee replacement surgery, treatment of venous thromboembolism (VTE) and nonvalvular atrial fibrillation, as well as treatment of DVT and pulmonary embolism ...
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive in-hospital and 30-day outcomes from the fully-enrolled 500-patient CLOUT registry. The company also reported positive results from a propensity-matched comparison of patients ...
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced three new data sets will be presented during Late-Breaking Clinical Trial sessions at the 2022 TCT (Transcatheter Cardiovascular Therapeutics) and the 2022 VEINS (Venous Endovascular ...
DEFIANCE is a randomized controlled trial (“RCT”) comparing the clinical outcomes of patients with iliofemoral deep vein thrombosis (“DVT”) treated with the ClotTriever System versus anticoagulation only. ...
Xarelto is approved for more venous and arterial thromboembolic (VAT) conditions than any other NOAC: The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors The treatment of pulmonary embolism (PE) in adults The treatment of deep vein thrombosis ...
ByBayer AG
Xarelto is the only Factor Xa anticoagulant FDA approved for pediatric patients and offers a flexible weight-based dosing Xarelto is available in both oral tablet and liquid suspension formulations for use in appropriate children less than 18 years of age Convenient liquid formulation advances standard of care for children; alleviates administration challenges found with injectable ...
ByBayer AG
Public reimbursement coverage reaches 9 Provinces in Canada Canadian private health plan coverage now exceeding 90% Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that it has successfully entered into a Product Listing Agreement (“PLA”) with Quebec Minister of Health, for ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the full approval of its Investigational Device Exemption (IDE) application by the FDA to conduct the pivotal STAR–D (Safe and Timely Antithrombotic Removal – Direct ...
Malvern, PA, December 1, 2020 Vesper Medical, Inc., a developer of medical devices for deep venous disease, today announced initiation of its U.S. Food and Drug Administration (FDA) Investigational Exemption (IDE) study – Venous stent for the Iliofemoral Vein Investigational clinical trial using the Vesper DUO Venous Stent System® (VIVID). ...
Inceptus Medical LLC, a medical device company incubator, announced today that it has completed a $4.5M Series B financing for Okami Medical Inc. The financing will provide the resources to develop and commercialize innovative devices for the interventional treatment of cardiovascular disease. The financing was led by members of the board of directors, U.S. Venture Partners (USVP) and medical ...
PLANO, Texas, Jan. 5, 2016 /PRNewswire/ -- Argon Medical Devices, Inc. announced the completed acquisition of three vascular products from Rex Medical, LLC. The OptionELITE™ Retrievable Vena Cava Filter, CLEANER™ Rotational Thrombectomy System, and UltraStream™ Chronic Hemodialysis Catheter are now wholly owned by Argon Medical Devices, Inc. Prior to this transaction, ...